Journals / European Journal of Rheumatology / 2020 / Cilt: 7 - Sayı: 3

Epigenetics and systemic sclerosis: An answer to disease onset and evolution?

Pages
147–156
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The epigenome is an attractive therapeutic target; however, successful epigenetics-basedtreatments require a better understanding of the molecular mechanisms controlling the epigenomeand its alteration in the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There is growing evidence that implicates epigenetic modification in the pathogenesis of systemicsclerosis (SSc).
📊
Key Findings & Data:We will review the current literature for factors that link epigeneticsto SSc by discussing DNA methylation, histone acetylation and methylation, and non-coding RNAs(ncRNAs), particularly microRNA changes in endothelial cells, fibroblasts (FBs), and lymphocytes.These three cell types are significantly involved in the early stages and throughout the course of thedisease and are particularly vulnerable to epigenetic regulation.
💡
Conclusion & Impact:The epigenome is an attractive therapeutic target; however, successful epigenetics-basedtreatments require a better understanding of the molecular mechanisms controlling the epigenomeand its alteration in the disease.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

There is growing evidence that implicates epigenetic modification in the pathogenesis of systemicsclerosis (SSc). The complexity of epigenetic regulation and its dynamic nature complicate the investigationof its role in the disease. We will review the current literature for factors that link epigeneticsto SSc by discussing DNA methylation, histone acetylation and methylation, and non-coding RNAs(ncRNAs), particularly microRNA changes in endothelial cells, fibroblasts (FBs), and lymphocytes.These three cell types are significantly involved in the early stages and throughout the course of thedisease and are particularly vulnerable to epigenetic regulation. The pathogenesis of SSc is likely relatedto modifications of the epigenome by environmental signals in individuals with a specific geneticmakeup. The epigenome is an attractive therapeutic target; however, successful epigenetics-basedtreatments require a better understanding of the molecular mechanisms controlling the epigenomeand its alteration in the disease.

🔖

Cite This Article

RAMAHİ, A., ALTOROK, N., KAHALEH, B. (2022). Epigenetics and systemic sclerosis: An answer to disease onset and evolution?. European Journal of Rheumatology, Cilt: 7 - Sayı: 3, 147–156. https://ajindex.com/articles/503207

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Altorok N, Almeshal N, Wang Y, Kahaleh B. Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2015 54: 1759-70. [Crossref] 2. Altorok N, Kahaleh B. Epigenetics and systemic sclerosis. Semin Immunopathol 2015
  2. [Crossref] 3. Aslani S, Sobhani S, Gharibdoost F, Jamshidi A, Mahmoudi M. Epigenetics and pathogenesis of systemic sclerosis
  3. the ins and outs. Hum Immunol 2018
  4. [Crossref] 4. Tsou PS, Sawalha AH. Unfolding the pathogenesis of scleroderma through genomics and epigenomics. J Autoimmun 2017
  5. [Crossref] 5. Walczyk M, Paradowska-Gorycka A, Olesinska M. Epigenetics: The future direction in systemic sclerosis. Scand J Immunol 2017
  6. [Crossref] 6. Murdaca G, Contatore M, Gulli R, Mandich P, Puppo F. Genetic factors and systemic sclerosis. Autoimmun Rev 2016
  7. [Crossref] 7. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol 2015
  8. [Crossref] 8. Sun X, Xiao Y, Zeng Z, Shi Y, Tang B, Long H, et al. All-trans retinoic acid induces CD4+CD25+- FOXP3+ regulatory t cells by increasing FOXP3 demethylation in systemic sclerosis CD4+ t cells. J Immunol Res 2018
  9. 8658156. [Crossref] 9. Makino T, Jinnin M. Genetic and epigenetic abnormalities in systemic sclerosis. J Dermatol 2016
  10. [Crossref] 10. Zuo X, Zhang L, Luo H, Li Y, Zhu H. Systematic approach to understanding the pathogenesis of systemic sclerosis. Clin Genet 2017
  11. [Crossref] 11. Rubio-Rivas M, Moreno R, Corbella X. Occupational and environmental scleroderma. Systematic review and meta-analysis Clin Rheumatol 2017
  12. [Crossref] 12. Ciechomska M, Zarecki P, Merdas M, Swierkot J, Morgiel E, Wiland P, et al. The role of microRNA- 5196 in the pathogenesis of systemic sclerosis. Eur J Clin Invest 2017
  13. [Crossref] 13. Lafyatis R. Editorial: Epigenetics in systemic sclerosis. Arthritis Rheumatol 2016
  14. [Crossref] 14. O'Reilly S, Ciechomska M, Fullard N, Przyborski S, van Laar JM. IL-13 mediates collagen deposition via STAT6 and microRNA-135b: A role for epigenetics. Sci Rep 2016
  15. 25066. [Crossref] 15. Schleithoff C, Voelter-Mahlknecht S, Dahmke IN, Mahlknecht U. On the epigenetics of vascular regulation and disease. Clin Epigenetics 2012
  16. [Crossref] 16. Szerlong HJ, Hansen JC. Nucleosome distribution and linker DNA: Connecting nuclear function to dynamic chromatin structure. Biochem Cel